Phenytoin, in single doses of 10 or 30 mg/kg, was administered by i.v. injection to nonpregnant (congruent to 200-300 g) and 20 days pregnant inbred Lewis rats. The plasma protein binding of phenytoin was determined under conditions which minimized in vitro lipolysis and consequent artifactual results. The absolute (milliliters per minute) plasma clearance of total (free plus bound) phenytoin by the pregnant rats was increased (10-mg/kg dose) or not significantly different (30-mg/kg dose) compared to concurrent nonpregnant controls. The relative (milliliters per minute per kilogram) plasma clearance of total phenytoin was not significantly changed (10-mg/kg dose) or was decreased (30-mg/kg dose) in pregnancy. The relative apparent volume of distribution of free drug (but not of total drug) was essentially the same in the pregnant and nonpregnant animals and was independent of dose. The plasma clearance of free (unbound) phenytoin decreased with dose and was decreased during pregnancy, at both doses studied (more so at the larger dose). The elimination kinetics of p- hydroxyphenytoin , the major metabolite of phenytoin which inhibits phenytoin metabolism in rats, were similar in pregnant and nonpregnant rats and so were the plasma concentrations of this metabolite after phenytoin administration. The relatively more pronounced effect of pregnancy on the elimination of the larger dose of phenytoin may reflect a greater inhibitory effect of p- hydroxyphenytoin during pregnancy. This does not occur in humans (due to much lower plasma concentrations of the metabolite) and that may account for possible differences in the effect of pregnancy on phenytoin pharmacokinetics in rats and humans.
Download full-text PDF |
Source |
---|
Lupus Sci Med
January 2025
Medicine, University of Washington, Seattle, Washington, USA.
Objectives: To study neutrophil gelatinase-associated lipocalin (NGAL) levels in peripheral blood in SLE, and to propose a mechanism by which neutrophils secrete NGAL on stimulation with immune complexes (IC).
Methods: NGAL was measured by ELISA in two independent Swedish SLE cohorts acting as exploratory and validation cohort (n=124 and n=308, respectively), disease controls (n=38) and healthy controls (n=77). NGAL levels were measured in supernatant from IC-stimulated neutrophils in the presence or absence of a toll-like receptor 8 inhibitor (TLR8i).
Clin Pharmacokinet
January 2025
College of Pharmacy, Kyungsung University, 309, Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea.
Background And Objective: Telmisartan exhibits significant pharmacokinetic (PK) variability, but it remains unclear whether its PK profile is altered in hypertensive patients. This study aimed to characterize telmisartan PKs by conducting a meta-analysis and developing a pooled population PK model based on data from healthy subjects and hypertensive patients.
Methods: Relevant literature was identified by a systematic approach.
J Clin Pharmacol
January 2025
Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
This study evaluates the impact of acute pyelonephritis in pregnant women on the in vivo activity of renal OAT3 using the endogenous biomarker (EB) 6β-hydroxycortisol (6β-OHF) renal clearance (CL 6β-OHF) and AUC validated by correlating with the secretion clearance (CL) of the probe drug furosemide. Additionally, 6β-OHF formation clearance (CL 6β-OHF) as well as urinary (Ae/Ae) and plasma (AUC/AUC) ratios were also evaluated as EB for hepatic CYP3A activity. Pregnant women in their third trimester of gestation, diagnosed with acute pyelonephritis, were recruited before (pre-treatment, n = 8) and after (post-treatment, n = 8) cefuroxime treatment and resolution of acute pyelonephritis.
View Article and Find Full Text PDFEpilepsia
January 2025
Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
Objective: Identifying factors influencing cannabidiol (CBD) exposure can optimize treatment efficacy and safety. We aimed to describe the population pharmacokinetics of CBD in children with drug-resistant developmental and epileptic encephalopathies (DEEs) and assess the influence of environmental, pharmacological, and clinical characteristics on CBD systemic exposure.
Methods: Data from two pharmacokinetic studies of patients aged 2-18 years with DEEs were included (N = 48 patients).
J Vet Pharmacol Ther
January 2025
Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.
The objective of this study was to implement population pharmacokinetic (PPK) of enrofloxacin (EF) in grass carp (Ctenopharyngodon idella) after a single oral administration and a single intravenous administration based on a nonlinear mixed effect model. The plasma samples collected by the sparse sampling method were detected by high-performance liquid chromatography with a fluorescent detector. The initial pharmacokinetic (PK) parameters were evaluated by reference search and the calculation of a naïve pooled method.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!